Hanmi Pharm Co (128940.KS) Stock Price

Hanmi Pharm Co Price

KOSDAQ·CLOSED
388,500.00KRW-4,500.00 (-1.15 %)
Market closed

Revenue has compounded at 6.3% per year over the past 17 years to 1.50 T KRW. Earnings per share have grown at 4.7% per year over the last 17 years. Hanmi Pharm Co's net margin stands at 8.1%, up from 1.1% several years earlier. Hanmi Pharm Co currently offers a dividend yield of about 0.32%. The payout ratio is around 13% of earnings. Analysts set a median price target of 540,600.00 KRW, implying 39.2% above the current price. Of 23 analysts, 22 rate the stock a buy — an overall Buy consensus. The stock trades about 37% above its 52-week low.

Hanmi Pharm Co stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Hanmi Pharm Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Hanmi Pharm Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Hanmi Pharm Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Hanmi Pharm Co Stock Price History
DateHanmi Pharm Co Price
8/19/2026388,500.00 KRW
8/18/2026393,000.00 KRW
8/14/2026398,500.00 KRW
8/13/2026399,000.00 KRW
8/12/2026396,000.00 KRW
8/11/2026414,000.00 KRW
8/10/2026402,500.00 KRW
8/7/2026392,500.00 KRW
8/6/2026382,000.00 KRW
8/5/2026386,500.00 KRW
8/4/2026378,000.00 KRW
8/3/2026351,000.00 KRW
7/31/2026333,500.00 KRW
7/30/2026319,500.00 KRW
7/29/2026322,000.00 KRW
7/28/2026374,500.00 KRW
7/27/2026394,500.00 KRW
7/24/2026392,000.00 KRW
7/23/2026389,000.00 KRW
7/22/2026369,000.00 KRW
7/21/2026372,500.00 KRW
7/20/2026376,000.00 KRW
7/16/2026386,000.00 KRW
7/15/2026387,500.00 KRW
7/14/2026350,500.00 KRW
7/13/2026390,500.00 KRW
7/10/2026395,500.00 KRW
7/9/2026402,000.00 KRW
7/8/2026409,000.00 KRW
7/7/2026430,000.00 KRW
7/6/2026423,000.00 KRW
7/3/2026456,000.00 KRW
7/2/2026419,000.00 KRW
7/1/2026418,000.00 KRW
6/30/2026405,500.00 KRW
6/29/2026422,000.00 KRW
6/26/2026361,000.00 KRW
6/25/2026407,500.00 KRW
6/24/2026401,500.00 KRW
6/23/2026377,000.00 KRW
6/22/2026403,500.00 KRW
6/19/2026412,500.00 KRW
6/18/2026426,000.00 KRW
6/17/2026445,000.00 KRW
6/16/2026421,000.00 KRW
6/15/2026424,500.00 KRW
6/12/2026422,000.00 KRW
6/11/2026406,500.00 KRW
6/10/2026411,500.00 KRW
6/9/2026428,500.00 KRW
6/8/2026413,000.00 KRW
6/5/2026506,000.00 KRW
6/4/2026498,500.00 KRW
6/2/2026507,000.00 KRW
6/1/2026524,000.00 KRW
5/29/2026491,500.00 KRW
5/28/2026486,500.00 KRW
5/27/2026489,500.00 KRW
5/26/2026454,500.00 KRW
5/22/2026453,500.00 KRW
5/21/2026443,000.00 KRW
5/20/2026418,500.00 KRW
5/19/2026439,500.00 KRW
5/18/2026432,500.00 KRW
5/15/2026478,000.00 KRW
5/14/2026449,500.00 KRW
5/13/2026445,000.00 KRW
5/12/2026454,500.00 KRW
5/11/2026423,500.00 KRW
5/8/2026436,000.00 KRW
5/7/2026430,500.00 KRW
5/6/2026434,500.00 KRW
5/4/2026445,000.00 KRW
4/30/2026460,000.00 KRW
4/29/2026483,000.00 KRW
4/28/2026491,500.00 KRW
4/27/2026494,500.00 KRW
4/24/2026497,500.00 KRW
4/23/2026490,000.00 KRW
4/22/2026494,500.00 KRW
4/21/2026504,000.00 KRW
4/20/2026529,000.00 KRW
4/17/2026533,000.00 KRW
4/16/2026528,000.00 KRW
4/15/2026512,000.00 KRW
4/14/2026501,000.00 KRW
4/13/2026510,000.00 KRW
4/10/2026500,000.00 KRW
4/9/2026487,000.00 KRW
4/8/2026493,500.00 KRW
4/7/2026507,000.00 KRW
4/6/2026500,000.00 KRW
4/3/2026507,000.00 KRW
4/2/2026505,000.00 KRW
4/1/2026552,000.00 KRW
3/31/2026515,000.00 KRW
3/30/2026524,000.00 KRW
3/27/2026549,000.00 KRW
3/26/2026551,000.00 KRW
3/25/2026541,000.00 KRW
3/24/2026511,000.00 KRW
3/23/2026501,000.00 KRW
3/20/2026560,000.00 KRW
3/19/2026519,000.00 KRW
3/18/2026531,000.00 KRW
3/17/2026520,000.00 KRW
3/16/2026500,000.00 KRW
3/13/2026496,500.00 KRW
3/12/2026488,000.00 KRW
3/11/2026490,000.00 KRW
3/10/2026511,000.00 KRW
3/9/2026481,500.00 KRW
3/6/2026516,000.00 KRW
3/5/2026519,000.00 KRW
3/4/2026478,000.00 KRW
3/3/2026571,000.00 KRW
2/27/2026593,000.00 KRW
2/26/2026594,000.00 KRW
2/25/2026591,000.00 KRW
2/24/2026616,000.00 KRW
2/23/2026616,000.00 KRW
2/20/2026610,000.00 KRW
2/19/2026621,000.00 KRW
2/13/2026601,000.00 KRW
2/12/2026614,000.00 KRW
2/11/2026626,000.00 KRW
2/10/2026591,000.00 KRW
2/9/2026563,000.00 KRW
2/6/2026552,000.00 KRW
2/5/2026541,000.00 KRW
2/4/2026540,000.00 KRW
2/3/2026503,000.00 KRW
2/2/2026467,000.00 KRW
1/30/2026484,000.00 KRW
1/29/2026505,000.00 KRW
1/28/2026519,000.00 KRW
1/27/2026475,000.00 KRW
1/26/2026481,000.00 KRW
1/23/2026465,500.00 KRW
1/22/2026430,500.00 KRW
1/21/2026415,000.00 KRW
1/20/2026445,000.00 KRW
1/19/2026444,500.00 KRW
1/16/2026436,500.00 KRW
1/15/2026436,500.00 KRW
1/14/2026424,500.00 KRW
1/13/2026431,000.00 KRW
1/12/2026481,500.00 KRW
1/9/2026477,000.00 KRW
1/8/2026463,000.00 KRW
1/7/2026464,000.00 KRW
1/6/2026469,000.00 KRW
1/5/2026452,000.00 KRW
1/2/2026443,000.00 KRW
12/30/2025452,000.00 KRW
12/29/2025451,000.00 KRW
12/26/2025450,500.00 KRW
12/24/2025440,500.00 KRW
12/23/2025440,000.00 KRW
12/22/2025438,000.00 KRW
12/19/2025441,000.00 KRW
12/18/2025434,000.00 KRW
12/17/2025434,500.00 KRW
12/16/2025436,500.00 KRW
12/15/2025448,000.00 KRW
12/12/2025445,500.00 KRW
12/11/2025450,000.00 KRW
12/10/2025433,500.00 KRW
12/9/2025428,000.00 KRW
12/8/2025421,500.00 KRW
12/5/2025426,000.00 KRW
12/4/2025430,000.00 KRW
12/3/2025434,000.00 KRW
12/2/2025430,000.00 KRW
12/1/2025451,000.00 KRW
11/28/2025456,500.00 KRW
11/27/2025449,500.00 KRW
11/26/2025455,500.00 KRW
11/25/2025444,500.00 KRW
11/24/2025446,000.00 KRW
11/21/2025445,500.00 KRW
11/20/2025456,500.00 KRW
11/19/2025450,000.00 KRW
11/18/2025461,000.00 KRW
11/17/2025474,000.00 KRW
11/14/2025473,000.00 KRW
11/13/2025483,000.00 KRW
11/12/2025479,500.00 KRW
11/11/2025454,000.00 KRW
11/10/2025443,500.00 KRW
11/7/2025439,000.00 KRW
11/6/2025443,500.00 KRW
11/5/2025459,000.00 KRW
11/4/2025451,500.00 KRW
11/3/2025424,000.00 KRW
10/31/2025425,000.00 KRW
10/30/2025390,500.00 KRW
10/29/2025393,500.00 KRW
10/28/2025405,500.00 KRW
10/27/2025428,000.00 KRW
10/24/2025339,000.00 KRW
10/23/2025344,500.00 KRW
10/22/2025349,000.00 KRW
10/21/2025343,500.00 KRW
10/20/2025353,500.00 KRW
10/17/2025346,000.00 KRW
10/16/2025342,500.00 KRW
10/15/2025352,000.00 KRW
10/14/2025342,000.00 KRW
10/13/2025349,000.00 KRW
10/10/2025354,500.00 KRW
10/2/2025354,500.00 KRW
10/1/2025360,500.00 KRW
9/30/2025367,000.00 KRW
9/29/2025372,500.00 KRW
9/26/2025377,000.00 KRW
9/25/2025375,000.00 KRW
9/24/2025393,000.00 KRW
9/23/2025384,500.00 KRW
9/22/2025366,000.00 KRW
9/18/2025333,500.00 KRW
9/17/2025312,000.00 KRW
9/16/2025319,000.00 KRW
9/15/2025299,000.00 KRW
9/12/2025296,000.00 KRW
9/11/2025292,000.00 KRW
9/10/2025291,000.00 KRW
9/9/2025290,500.00 KRW
9/8/2025306,000.00 KRW
9/5/2025305,500.00 KRW
9/4/2025304,500.00 KRW
9/3/2025305,000.00 KRW
9/2/2025309,000.00 KRW
9/1/2025304,000.00 KRW
8/29/2025303,000.00 KRW
8/28/2025303,500.00 KRW
8/27/2025300,000.00 KRW
8/26/2025298,000.00 KRW
8/25/2025290,000.00 KRW
8/22/2025283,000.00 KRW
Access this data via the Eulerpool API
Get Free API Key

Hanmi Pharm Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
1.20 T KRW
125.42 B KRW
67.03 B KRW
Jan 1, 2022
1.33 T KRW
158.09 B KRW
82.79 B KRW
Jan 1, 2023
1.49 T KRW
220.69 B KRW
146.23 B KRW
Jan 1, 2024
1.50 T KRW
216.19 B KRW
121.32 B KRW
Jan 1, 2025 (e)
1.53 T KRW
298.49 B KRW
166.64 B KRW
Jan 1, 2026 (e)
1.68 T KRW
327.16 B KRW
209.47 B KRW
Jan 1, 2027 (e)
1.78 T KRW
347.57 B KRW
218.13 B KRW
Jan 1, 2028 (e)
1.92 T KRW
374.86 B KRW
241.00 B KRW

Hanmi Pharm Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 21, 2026, 12:55 PM
 
REVENUET KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMET KRW
EBITB KRW
EBIT MARGIN%
NET INCOMEB KRW
NET INCOME GROWTH%
DIV.KRW
DIV. GROWTH%
SHARESM
2013201420152016201720182019202020212022202320242025e2026e2027e2028e
0.730.761.320.880.921.021.111.081.201.331.491.501.531.681.781.92
8.334.2773.07-33.003.8410.849.62-3.3911.8410.6711.970.312.489.606.247.85
57.0455.5069.7752.2156.5653.2456.7954.0052.5953.9655.6254.6354.6354.6354.6354.63
0.420.420.920.460.520.540.630.580.630.720.830.820.840.920.971.05
61.9034.45211.8026.7782.1683.57103.8848.98125.42158.09220.69216.19298.49327.16347.57374.86
8.484.5316.083.038.968.239.334.5510.4211.8714.8014.4619.4819.4819.4819.48
43.9335.51154.4423.3360.4324.8952.1111.9667.0382.79146.23121.32166.64209.47218.13241.00
94.08-19.17334.93-84.90159.08-58.81109.35-77.05460.4623.5276.63-17.0437.3625.704.1410.49
––2,000.001,595.31490.20490.20490.20490.20490.20490.20490.201,250.002,100.002,520.003,024.00–
–––-20.23-69.27––––––155.0068.0020.0020.00–
11.0011.0012.0012.0012.0012.0012.0012.0012.7212.7012.6912.6812.6812.6812.6812.68
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Hanmi Pharm Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Hanmi Pharm Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Hanmi Pharm Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Hanmi Pharm Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Hanmi Pharm Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Hanmi Pharm Co stock margins

The Hanmi Pharm Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hanmi Pharm Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hanmi Pharm Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
54.00 %
4.55 %
1.11 %
Jan 1, 2021
52.59 %
10.42 %
5.57 %
Jan 1, 2022
53.96 %
11.87 %
6.22 %
Jan 1, 2023
55.62 %
14.80 %
9.81 %
Jan 1, 2024
54.63 %
14.46 %
8.11 %
Jan 1, 2025 (e)
54.63 %
19.48 %
10.87 %
Jan 1, 2026 (e)
54.63 %
19.48 %
12.47 %
Jan 1, 2027 (e)
54.63 %
19.48 %
12.22 %

Hanmi Pharm Co Stock Revenue, EBIT, Earnings per Share

The Hanmi Pharm Co earnings per share therefore indicates how much revenue Hanmi Pharm Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
89,654.50 KRW
4,081.33 KRW
996.58 KRW
Jan 1, 2021
94,597.50 KRW
9,860.51 KRW
5,269.70 KRW
Jan 1, 2022
104,816.48 KRW
12,444.53 KRW
6,517.19 KRW
Jan 1, 2023
117,473.19 KRW
17,389.16 KRW
11,522.16 KRW
Jan 1, 2024
117,934.32 KRW
17,048.31 KRW
9,566.83 KRW
Jan 1, 2025 (e)
120,861.45 KRW
23,539.05 KRW
13,141.37 KRW
Jan 1, 2026 (e)
132,467.73 KRW
25,799.49 KRW
16,518.31 KRW
Jan 1, 2027 (e)
140,731.55 KRW
27,408.95 KRW
17,201.44 KRW

Hanmi Pharm Co business model & stock analysis

Hanmi Pharm Co Ltd. is a leading biopharmaceutical company based in Seoul, South Korea. Since its establishment in 1973, the company has focused on the development and marketing of innovative therapeutics for the treatment of serious diseases. The history of Hanmi Pharm is characterized by continuous growth and groundbreaking successes. Over the past 50 years, the company has become a key player in the biopharmaceutical industry, with branches in Europe, America, and Asia. Hanmi Pharm's business model is focused on developing and selling innovative drugs that target core competencies such as oncology, immunology, metabolic diseases, and rare diseases. The company has several research facilities where highly qualified scientists work to develop new and more effective therapies. Hanmi Pharm is divided into three different divisions: drug development, manufacturing, and distribution. In the drug development division, the company works on discovering new compounds and medications for the treatment of various diseases. In the manufacturing division, the company produces the corresponding drugs under the highest quality standards. In the distribution area, Hanmi Pharm distributes its products worldwide and ensures that they always meet the high requirements of regulatory authorities. In recent years, Hanmi Pharm has brought an impressive range of products to the market, including drugs for the treatment of cancer, diabetes, cardiovascular diseases, and other serious conditions. Here are some of the company's most well-known products: - Lapsiratase: A novel drug for the treatment of acute myeloid leukemia. Lapsiratase was developed by Hanmi Pharm in partnership with a European company and has already shown promising results in clinical trials. - Insulin Glargine: A basal insulin analog used for the treatment of diabetes. The medication is approved in Europe and Canada and is manufactured by Hanmi Pharm in collaboration with a European company. - Olita (Olmesartan medoxomil): An antihypertensive drug prescribed for the treatment of high blood pressure. Olita is a well-known medication from Hanmi Pharm and is distributed worldwide. - Biosimilars: In recent years, Hanmi Pharm has also invested extensively in the development of biosimilars. These biological imitations of original drugs are a cost-effective alternative to expensive biopharmaceuticals and can provide many patients with access to crucial therapy options. Hanmi Pharm aims to continue developing and bringing innovative drugs to the market that improve people's lives and provide better treatment options for seriously ill patients.

Hanmi Pharm Co SWOT Analysis

Strengths

Hanmi Pharm Co Ltd possesses several strengths that contribute to its competitive advantage in the market. These include:

  • Strong market presence and brand reputation
  • Diverse portfolio of high-quality pharmaceutical products
  • Robust research and development capabilities
  • Advanced manufacturing facilities
  • Strong distribution network

Weaknesses

Despite its strengths, Hanmi Pharm Co Ltd also faces certain weaknesses that may hinder its growth potential. These include:

  • Dependency on a limited number of key products
  • Relatively lower market share compared to some competitors
  • Vulnerability to changing market dynamics and regulations
  • High level of competition in the pharmaceutical industry
  • Challenges in maintaining cost competitiveness

Opportunities

Hanmi Pharm Co Ltd can leverage the following opportunities to expand its market presence and drive growth:

  • Increasing demand for innovative pharmaceutical solutions
  • Expansion into emerging markets with growing healthcare needs
  • Collaboration with strategic partners for research and development
  • Strategic acquisitions or partnerships to broaden product offerings
  • Advancements in technology that enable new product development

Threats

Hanmi Pharm Co Ltd should be cautious of the following threats that may pose challenges to its business operations:

  • Intense competition from both domestic and international pharmaceutical companies
  • Increasing regulatory scrutiny and compliance requirements
  • Price pressures and potential reimbursement challenges
  • Product counterfeit and patent infringement risks
  • Political and economic uncertainties affecting the healthcare industry

Hanmi Pharm Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Hanmi Pharm Co historical P/E ratio, EBIT multiple, and P/S ratio

Hanmi Pharm Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Hanmi Pharm Co shares outstanding

The number of shares of Hanmi Pharm Co was 12.68 M in 2025. This indicates how many shares Hanmi Pharm Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
12.00 M Stocks
Jan 1, 2021
12.72 M Stocks
Jan 1, 2022
12.70 M Stocks
Jan 1, 2023
12.69 M Stocks
Jan 1, 2024
12.68 M Stocks
Jan 1, 2025 (e)
12.68 M Stocks
Jan 1, 2026 (e)
12.68 M Stocks
Jan 1, 2027 (e)
12.68 M Stocks

Hanmi Pharm Co stock splits

In Hanmi Pharm Co's history, there have been no stock splits.

Hanmi Pharm Co Dividend History

11 years of dividend payments

YearAnnual DividendYoY ChangePayments
20262,000.00KRWYTD—1×
Mar 30, 20262,000.00KRW↑ 100.0%1/1
20241,250.00KRW↑ 155.0%2×
2023490.20KRW 0.0%1×
2022490.20KRW 0.0%1×
2021490.20KRW 0.0%1×
2020490.20KRW↑ 0.0%1×
2019490.20KRW 0.0%1×
2018490.20KRW 0.0%1×
2017490.20KRW↓ 69.3%1×
20161,595.31KRW↓ 20.2%—

Hanmi Pharm Co dividend history and estimates

In 2025, Hanmi Pharm Co paid a dividend amounting to 2,100.00 KRW. Dividend means that Hanmi Pharm Co distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2020
490.20 KRW
0.00 KRW
Jan 1, 2021
490.20 KRW
0.00 KRW
Jan 1, 2022
490.20 KRW
0.00 KRW
Jan 1, 2023
490.20 KRW
0.00 KRW
Jan 1, 2024
1,250.00 KRW
0.00 KRW
Jan 1, 2025 (e)
0.00 KRW
2,100.00 KRW
Jan 1, 2026 (e)
0.00 KRW
2,520.00 KRW
Jan 1, 2027 (e)
0.00 KRW
3,024.00 KRW

Hanmi Pharm Co dividend payout ratio

In 2025, Hanmi Pharm Co had a payout ratio of 15.98%. The payout ratio indicates the percentage of the company's profits that Hanmi Pharm Co distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
47.28 %
Jan 1, 2021
9.12 %
Jan 1, 2022
7.52 %
Jan 1, 2023
4.34 %
Jan 1, 2024
13.07 %
Jan 1, 2025 (e)
15.98 %
Jan 1, 2026 (e)
15.26 %
Jan 1, 2027 (e)
17.58 %

Current Hanmi Pharm Co forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.92 %
Buy
95.65 % (22)
Hold
4.35 % (1)
Sell
0.00 % (0)
12M Price Target
540,600.00
Last Price
401,500.00
Currency
KRW
12M Return Potential
34.65 %
LTM Return
0 %

Hanmi Pharm Co Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
4/24/20243,356.54KRW-394.06 BKRW-2024 Q1
2/6/20242,964.06KRW-398.70 BKRW-2023 Q4

EESG©

Eulerpool ESG Scorecard© for the Hanmi Pharm Co stock

79/100
99
Environment
99
Social
39
Governance
E

Environment

20
Scope 1 - Direct Emissions11,541
Scope 2 - Indirect emissions from purchased energy74,824
Scope 3 - Indirect emissions within the value chain82,554.5
Total CO₂ emissions86,363
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees37.413
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Hanmi Pharm Co shareholder structure

% Name
12.41041%
National Pension Service
National Pension Service
1.42553%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.92463%
JPMorgan Asset Management (Asia Pacific) Limited
JPMorgan Asset Management (Asia Pacific) Limited
0.61294%
Samsung Asset Management Co., Ltd.
Samsung Asset Management Co., Ltd.
0.55843%
Mirae Asset Global Investments Co., Ltd.
Mirae Asset Global Investments Co., Ltd.
0.55815%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
...

Hanmi Pharm Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
49.5%
Float Shares
-
Shares Outstanding
-

Hanmi Pharm Co Executives and Management Board

37 members · avg. age 54 · 19 % women

JP

Mr. Jae Hyeon Park (56)

Co-President, Chief Executive Officer, Director

587.00 M KRW

Management

JY

Mr. Jong Hun Yim (47)

Co-President, Director

522.00 M KRW
YC

Mr. Yin Yeong Choi (54)

Managing Director

–
MP

Ms. Myeong Hui Park (55)

Managing Director

–
JP

Mr. Jung Hyeon Park (59)

Managing Director · since 2022

–
SG

Mr. Sun Gi Gwon (47)

Managing Director

–
NK

Ms. Na Yeong Kim (49)

Managing Director · since 2022

–

Board of Directors

YS

Ms. Yeong Suk Song (76)

Chairman

1.11 B KRW
JY

Ms. Ju Hyeon Yim (50)

Vice Chairman · since 2024

603.00 M KRW
JK

Mr. Jae Gyo Kim (56)

Other Non-Executive Director

–
DS

Mr. Dong Guk Shin (75)

Other Non-Executive Director

–
TK

Mr. Tae Yun Kim (63)

Non-Executive Independent Director

–
YL

Mr. Yeong Gu Lee (66)

Non-Executive Independent Director

–

Hanmi Pharm Co Supply Chain

Hanmi Pharm Co Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
16 companies
#Nameβ 1YTrend
1
Hwail Pharmaceutical
Supplier·Customer·Pharmaceuticals·KR
-0.53
0.29
0.20
0.71
0.87
0.56
—
2
Spectrum Pharmaceuticals
Supplier·Customer·Biotechnology·US
-0.75
-0.18
-0.42
-0.09
0.65
0.51
—
3
Innovent Biologics
Supplier·Customer·Biotechnology·CN
0.63
0.46
-0.53
-0.43
0.37
0.47
—
4
CrystalGenomics
Supplier·Customer·Biotechnology·KR
0.31
0.52
-0.50
-0.47
0.43
0.40
—
5
Legochem Biosciences
Supplier·Customer·Life Sciences Tools & Services·KR
0.83
0.38
-0.63
-0.31
0.37
0.38
0.43
#Nameβ 1YTrend
1
Organon
Customer·Pharmaceuticals·US
0.81
0.16
-0.36
0.18
-0.34
—
—
2
Roche Holding
Supplier·Customer·Pharmaceuticals·CH
-0.86
-0.03
0.64
0.13
-0.26
-0.57
-0.09
3
RAPT Therap
Supplier·Customer·Biotechnology·US
-0.42
0.39
-0.55
-0.49
0.03
-0.40
0.05
4
Merck & Co
Supplier·Customer·Pharmaceuticals·US
0.91
0.49
0.73
0.65
0
-0.24
0.00
5
Impinj
Supplier·Semiconductors & Semiconductor Equipment·US
-0.47
0.05
-0.77
-0.77
-0.72
-0.19
-0.60

Frequently asked questions about Hanmi Pharm Co

The business model of Hanmi Pharm Co Ltd is focused on pharmaceutical research and development, manufacturing, and sales. Hanmi Pharm specializes in developing innovative drugs for various therapeutic areas including diabetes, cardiovascular diseases, cancer, and rare diseases. The company also actively engages in strategic collaborations and licensing agreements to expand its product pipeline and market reach globally. Hanmi Pharm strives to enhance patients' quality of life through its advanced healthcare solutions and aims to become a leading global biopharmaceutical company.

Hanmi Pharm Co Ltd is primarily active in the pharmaceutical industry.

The main competitors of Hanmi Pharm Co Ltd in the market include multinational pharmaceutical companies such as Pfizer, Novartis, and AstraZeneca. These companies have a global presence and offer a wide range of pharmaceutical products and solutions, making them strong competitors in the industry. Despite facing competition from these established players, Hanmi Pharm Co Ltd has carved a niche for itself through its focus on innovative drug development, strategic partnerships, and strong distribution networks. This enables Hanmi Pharm Co Ltd to maintain its competitiveness and continue to thrive in the pharmaceutical market.

Hanmi Pharm Co Ltd, established in 1973, is a leading pharmaceutical company based in South Korea. With a strong focus on research and development, Hanmi Pharm has grown to become a global player in the healthcare industry. The company specializes in the development, manufacturing, and commercialization of innovative and high-quality pharmaceutical products. Hanmi Pharm's dedication to innovation has led to significant breakthroughs in various therapeutic areas, including oncology, diabetes, and rare diseases. The company's commitment to excellence and its strategic partnerships have enabled it to expand its presence and impact in markets worldwide. Hanmi Pharm Co Ltd continues to strive towards improving global healthcare by delivering innovative solutions and improving patients' lives.

Hanmi Pharm Co Ltd has achieved several significant milestones throughout its history. One notable accomplishment for the company was the successful development and commercialization of their anti-diabetic drug, Empagliflozin. This drug has become a breakthrough in the treatment of type 2 diabetes and has garnered recognition worldwide. Another milestone for Hanmi Pharm Co Ltd was the establishment of strategic partnerships with renowned global pharmaceutical companies, such as Sanofi and Boehringer Ingelheim, further enhancing their presence in the international market. These achievements highlight Hanmi Pharm Co Ltd's commitment to research and innovation, positioning them as a notable player in the pharmaceutical industry.

Hanmi Pharm Co Ltd is primarily present in South Korea.

Hanmi Pharm Co Ltd is a renowned pharmaceutical company that values innovation, integrity, and excellence. With a strong corporate philosophy focused on improving global health, Hanmi Pharm Co Ltd strives to develop cutting-edge solutions and provide accessible healthcare to people worldwide. Through continuous research and development, the company emphasizes improving patient outcomes and enhancing the quality of life. Hanmi Pharm Co Ltd's commitment to these values has enabled it to establish a strong presence in the industry and gain recognition for its high-quality products and services.

Analysts currently set an average price target of 507,085.71 KRW for the Hanmi Pharm Co stock (median: 540,600.00 KRW), implying +26.3 % versus the latest price. The consensus is based on 23 analyst ratings.

Hanmi Pharm Co Analyst Price Targets 2026

23 analysts currently rate the Hanmi Pharm Co stock: 22 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Hanmi Pharm Co to generate revenue of 1.68 T KRW and earnings per share of 16,518.31 KRW.

Hanmi Pharm Co Analyst Price Targets 2026

Converted at the current exchange rate, the Hanmi Pharm Co share trades at 238.34 EUR (388,500.00 KRW).

Hanmi Pharm Co Ltd is a leading biopharmaceutical company based in South Korea. The company operates in various sectors including the development, production, and marketing of pharmaceuticals and pharmaceutical products, diagnostic devices, and medical equipment. It specializes in the production of biosimilars, diagnostic devices, and medical equipment. It is focused on expanding its business model through partnerships and international market expansion.

The expected revenue of Hanmi Pharm Co is 1.68 T KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Hanmi Pharm Co is 209.47 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Hanmi Pharm Co is currently 23.52. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hanmi Pharm Co stock.

The price-to-sales ratio (P/S) of Hanmi Pharm Co is currently 2.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hanmi Pharm Co stock.

The Eulerpool Quality Score for Hanmi Pharm Co is 7/10.

The ISIN of Hanmi Pharm Co is KR7128940004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Hanmi Pharm Co is 128940.KS. The ticker symbol is used to trade Hanmi Pharm Co shares on the stock exchange.

Over the past 12 months, Hanmi Pharm Co paid a dividend of 1,250.00 KRW . This corresponds to a dividend yield of about 0.32 %. For the coming 12 months, Hanmi Pharm Co is expected to pay a dividend of 3,024.00 KRW.

The current dividend yield of Hanmi Pharm Co is 0.32 %.

Hanmi Pharm Co pays a dividend, distributed in the months of , , , .

Hanmi Pharm Co paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 3,024.00 KRW are expected. This corresponds to a dividend yield of 0.78 %.

Hanmi Pharm Co is assigned to the 'Health' sector.

In the year 2025, Hanmi Pharm Co distributed 1,750 KRW as dividends.

The dividends of Hanmi Pharm Co are distributed in KRW.

All fundamentals and in-depth analysis of Hanmi Pharm Co

Our stock analysis for Hanmi Pharm Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hanmi Pharm Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Hanmi Pharm Co Stock
Hanmi Pharm Co Revenue→
Hanmi Pharm Co Stock
Hanmi Pharm Co Net Income→
Hanmi Pharm Co Stock
Hanmi Pharm Co P/E→
Hanmi Pharm Co Stock
Hanmi Pharm Co P/S→
Hanmi Pharm Co Stock
Hanmi Pharm Co EBIT→
Hanmi Pharm Co Stock
Hanmi Pharm Co Dividend→
Hanmi Pharm Co Stock
Hanmi Pharm Co Directors Dealings→
Hanmi Pharm Co Stock
Hanmi Pharm Co Stocks→
Hanmi Pharm Co Stock
Hanmi Pharm Co Market capitalization→
Hanmi Pharm Co Stock
Hanmi Pharm Co Debt→
Hanmi Pharm Co Stock
Hanmi Pharm Co Liabilities→
Hanmi Pharm Co Stock
Hanmi Pharm Co Equity→
Hanmi Pharm Co Stock
Hanmi Pharm Co AAQS→
Hanmi Pharm Co Stock
Hanmi Pharm Co Employees→
Hanmi Pharm Co Stock
Hanmi Pharm Co ROE→
Hanmi Pharm Co Stock
Hanmi Pharm Co ROA→
Hanmi Pharm Co Stock
Hanmi Pharm Co ROCE→
Hanmi Pharm Co Stock
Hanmi Pharm Co News→
Hanmi Pharm Co Stock
Hanmi Pharm Co Analyst Price Targets→

Health Stocks

Hanmi Science CoHangzhou Tigermed Consulting CoHans BiomedHangzhou TianMuShan Pharmaceutical Enterprise CoHansa BiopharmaHangzhou Biotest Biotech CoHanshang Group CoHangzhou Bio-Sincerity Pharma-Tech CoHansoh Pharmaceutical Group CompanyHangzhou Alltest Biotech CoHapvida Participacoes e InvestimentosHangzhou AGS MedTech CoAll Stocks A–Z →